During the trial, Olesoxime is dosed at 330mg oral capsules once a day and riluzole is dosed in both arms at 50mg twice a day.
In total, the company has involved around 500 patients in the trial.
The primary end-point of the study is the overall 18 month survival rate.
Trophos chief medical officer Jean-Louis Abitbol said they are all looking forward with great anticipation to the results of the study, due before the end of the year.